Suzhan Zhang
Overview
Explore the profile of Suzhan Zhang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
92
Citations
1567
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
N4BP3 promotes breast cancer metastasis via NEDD4-mediated E-cadherin ubiquitination and degradation
Luo M, Li J, Yang Q, Xu S, Zhang K, Chen J, et al.
Cancer Lett
. 2022 Sep;
550:215926.
PMID: 36162713
The molecular mechanisms driving metastatic progression in breast cancer patients remain poorly understood. Here, we identified N4BP3 as a new regulator in promoting breast cancer metastasis. N4BP3 is enriched in...
12.
Wu Y, Gong X, Wang K, Yu C, Qiu J, Zhang S, et al.
Comb Chem High Throughput Screen
. 2022 Jun;
26(5):1030-1041.
PMID: 35718967
Background: Turning the "cold" tumor immune microenvironment into "hot" is a critical issue in cancer treatment today. Hormone receptor-rich breast cancer (HR+ BC) was previously considered immunologically quiescent. Objective: This...
13.
Yuan Z, Weng S, Ye C, Hu H, Zhang S, Yuan Y
Chin J Cancer Res
. 2022 Jun;
34(2):67-70.
PMID: 35685997
No abstract available.
14.
Luo M, Chen H, Deng H, Jin Y, Wang G, Zhang K, et al.
Front Oncol
. 2022 Jun;
12:881047.
PMID: 35656513
Purpose: Postmastectomy radiotherapy (PMRT) after neoadjuvant chemotherapy (NAC) in breast cancer patients with initial clinical stage cTN, especially for those who achieved ypTN, is still controversial. This study was to...
15.
Wang F, Dai G, Deng Y, Tang Y, Wang W, Niu Z, et al.
Chin J Cancer Res
. 2021 Sep;
33(4):490-499.
PMID: 34584374
Objective: Bevacizumab has an important and evolving role in improving outcomes in patients with metastatic colorectal cancer (mCRC) worldwide and was approved in China in 2010. However, there are limited...
16.
Dong C, Ding Y, Weng S, Li G, Huang Y, Hu H, et al.
Chin J Cancer Res
. 2021 Jul;
33(3):302-307.
PMID: 34321827
No abstract available.
17.
Yang M, Li D, Jiang W, Zhu L, Ju H, Sun Y, et al.
Ther Adv Med Oncol
. 2021 Jun;
13:17588359211023290.
PMID: 34178123
Background: This multicenter study aimed to reveal the genetic spectrum of colorectal cancer (CRC) with deficient mismatch repair (dMMR) and build a screening model for Lynch syndrome (LS). Methods: Through...
18.
Huang Y, Cai S, Li Q, Song Y, Yuan Y, Zhang S, et al.
Cancer Epidemiol
. 2021 May;
73:101937.
PMID: 33941483
Objective: To evaluate the impact of a colorectal cancer (CRC) risk predicting system on CRC mortality rates. Method: An organized population screening program targeted at all the subjects (n = ...
19.
Chen Q, Hu Y, Fang Z, Ye M, Li J, Zhang S, et al.
Front Chem
. 2021 Jan;
8:606495.
PMID: 33392149
Oxidative nucleic acid modifications have attracted increasing attention in recent years since they have been found to be related to a number of diseases including cancer. 8-Hydroxy-2'-deoxyguanosine (8-OHdG) and 8-hydroxyguanosine...
20.
Wang Y, Zhang Y, Du Y, Zhou M, Hu Y, Zhang S
Cell Biosci
. 2020 Dec;
10(1):136.
PMID: 33292526
N6-Methyladenosine (mA) is the most abundant, dynamic, and reversible epigenetic RNA modification that is found in coding and non-coding RNAs. Emerging studies have shown that mA and its regulators affect...